HUMANE CD30 LIGAND ANTIGEN BINDENDE PROTEINE

European patent · EP2841456 · In force

Register entry

Publication number
EP2841456
Application number
EP13720714
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Apr 25, 2013
Published
Mar 4, 2015
Granted
Jun 13, 2018
Protection ends at the latest
Apr 24, 2033
Next annual fee due
Apr 30, 2027
IPC classes
C07K 16/28 (2006.01)
Priority
US 201261639637 P 27.04.2012
PCT application
PCT/US2013/038135 25.04.2013
PCT publication
WO2013/163377 31.10.2013
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. May 1, 2026

    Change

    Published in Swissreg on 01.05.2026

  2. May 1, 2025

    Change

    Published in Swissreg on 01.05.2025

  3. May 1, 2024

    Change

    Published in Swissreg on 01.05.2024

  4. May 1, 2023

    Change

    Published in Swissreg on 01.05.2023

  5. Sep 12, 2018

    Agent entered

    Representative
    Novagraaf International SA, Chemin de l'Echo 3, 1213 Onex

    Published in Swissreg on 12.09.2018

  6. Jun 13, 2018

    Granted

    Published in Swissreg on 13.06.2018

Parties

Holder

Novo Nordisk A/S

Novo Allé, 2880 Bagsværd, DK

Amgen Inc.

One Amgen Center Drive, Thousand Oaks, California 91320-1799, US

Agent

Novagraaf International SA

Chemin de l'Echo 3, 1213 Onex

Inventor

ANDERSEN, Mette, Dahl

2880 Bagsværd, DK

DANTZLER, Jeff

Seattle, WA 98133, US

ARMITAGE, Richard, J.

Bainbridge Island, WA 98110, US

CLARK, Rutilio

Bainbridge Island, WA 98110, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.